Capnia (NASDAQ: SLNO) is one of 79 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its peers? We will compare Capnia to related businesses based on the strength of its dividends, risk, profitability, analyst recommendations, earnings, institutional ownership and valuation.
This table compares Capnia and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Capnia and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Capnia||$1.45 million||-$12.06 million||-0.84|
|Capnia Competitors||$975.11 million||$120.37 million||225.87|
Capnia’s peers have higher revenue and earnings than Capnia. Capnia is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Capnia has a beta of 5.99, suggesting that its stock price is 499% more volatile than the S&P 500. Comparatively, Capnia’s peers have a beta of 0.93, suggesting that their average stock price is 7% less volatile than the S&P 500.
Institutional and Insider Ownership
65.6% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 69.8% of Capnia shares are owned by insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for Capnia and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Capnia currently has a consensus target price of $8.00, indicating a potential upside of 365.12%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.86%. Given Capnia’s stronger consensus rating and higher possible upside, equities analysts clearly believe Capnia is more favorable than its peers.
Capnia peers beat Capnia on 7 of the 12 factors compared.
Capnia Company Profile
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
Receive News & Ratings for Capnia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capnia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.